Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIM ImmunoTech Inc AIM

Healthcare Biotechnology
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called... see more

Recent & Breaking News (NYSEAM:AIM)

Gainey & McKenna Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Hemispherx Biopharma, Inc. -- HEB

Troy Schwensen December 28, 2012

Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Hemispherx Biopharma, Inc.

PR Newswire December 28, 2012

CORRECTING and REPLACING -- SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Hemispherx Biopharma, Inc., and Certain Officers -- HEB

Troy Schwensen December 28, 2012

Rosen Law Firm Announces Filing of Securities Fraud Class Action Against Hemispherx Biopharma, Inc. - HEB

Troy Schwensen December 24, 2012

SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Hemispherx Biopharma, Inc., and Certain Officers -- HEB

Troy Schwensen December 24, 2012

FDA Advisory Committee Makes Recommendations on Ampligen (R) for Chronic Fatigue Syndrome

Troy Schwensen December 21, 2012

Swine flu-related stocks end the day down: update

Stockhouse Editorial April 29, 2009

Noveko board buzzing on swine flu, share price

Buzz on the Boards April 29, 2009